<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00439777</url>
  </required_header>
  <id_info>
    <org_study_id>11702b</org_study_id>
    <secondary_id>2006-004495-13</secondary_id>
    <nct_id>NCT00439777</nct_id>
  </id_info>
  <brief_title>Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study</brief_title>
  <official_title>Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority
      program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with
      confirmed acute symptomatic pulmonary embolism (PE) with or without symptomatic Deep-Vein
      Thrombosis (DVT) (Einstein-PE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Within the US 'Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.' is sponsor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment</measure>
    <time_frame>3-, 6-, or 12-month study treatment period</time_frame>
    <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality Until the Intended End of Study Treatment</measure>
    <time_frame>3-, 6-, or 12-month study treatment period</time_frame>
    <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Event for Net Clinical Benefit 1 Until the Intended End of Study Treatment</measure>
    <time_frame>3-, 6-, or 12-month study treatment period</time_frame>
    <description>Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Recurrent PE Until the Intended End of Study Treatment</measure>
    <time_frame>3-, 6- or 12-month study treatment period</time_frame>
    <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Recurrent DVT Until the Intended End of Study Treatment</measure>
    <time_frame>3-, 6- or 12-month study treatment period</time_frame>
    <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinically Relevant Bleeding, Treatment-emergent (Time Window: Until 2 Days After Last Dose)</measure>
    <time_frame>3-, 6- or 12-month study treatment period</time_frame>
    <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With All Deaths</measure>
    <time_frame>3-, 6- or 12-month study treatment period</time_frame>
    <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Other Vascular Events, On-treatment (Time Window: Until 1 Day After Last Dose)</measure>
    <time_frame>3-, 6- or 12-month study treatment period</time_frame>
    <description>All pre-defined vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism or vascular death) were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based results/films/images of confirmatory testing, and/or case summaries.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants With the Individual Components of Efficacy Outcomes Until the Intended End of Study Treatment</measure>
    <time_frame>3-, 6- or 12-month study treatment period</time_frame>
    <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Symptomatic Recurrent VTE (i.e. the Composite of Recurrent DVT or Fatal or Non-fatal PE) During Observational Period</measure>
    <time_frame>Up to 30 days after the last intake of study medication</time_frame>
    <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality During Observational Period</measure>
    <time_frame>Up to 30 days after the last intake of study medication</time_frame>
    <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With an Event for Net Clinical Benefit 1 During Observational Period</measure>
    <time_frame>Up to 30 days after the last intake of study medication</time_frame>
    <description>Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Recurrent DVT During Observational Period</measure>
    <time_frame>Up to 30 days after the last intake of study medication</time_frame>
    <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With the Individual Components of Efficacy Outcomes During Observational Period</measure>
    <time_frame>Up to 30 days after the last intake of study medication</time_frame>
    <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4833</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban (Xarelto, BAY59-7939)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin/VKA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY59-7939)</intervention_name>
    <description>During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.</description>
    <arm_group_label>Rivaroxaban (Xarelto, BAY59-7939)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin overlapping with and followed by VKA</intervention_name>
    <description>Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 hr before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.</description>
    <arm_group_label>Enoxaparin/VKA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed acute symptomatic proximal PE with or without symptomatic DVT

        Exclusion Criteria:

          -  Legal lower age limitations (country specific)

          -  Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the
             current episode of DVT and/or PE

          -  Other indication for VKA than DVT and/or PE

          -  The pre-randomization anti-coagulant treatment (Criteria # 4) has been prolonged from
             36 hours to a maximum of 48 hours.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92373</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <zip>33744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fredericksburg</city>
        <state>Virginia</state>
        <zip>22401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Escaldes - Engordany</city>
        <country>Andorra</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garran</city>
        <state>Australian Capital Territory</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lismore</city>
        <state>New South Wales</state>
        <zip>2480</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2229</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Redcliffe</city>
        <state>Queensland</state>
        <zip>4020</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Launceston</city>
        <state>Tasmania</state>
        <zip>7250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3135</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Feldkirch</city>
        <state>Vorarlberg</state>
        <zip>6807</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1171</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duffel</city>
        <zip>2570</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lier</city>
        <zip>2500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zottegem</city>
        <zip>9620</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80050-350</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Londrina</city>
        <state>Parana</state>
        <zip>86038440</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Botucatu</city>
        <state>Sao Paulo</state>
        <zip>18618 000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sorocaba</city>
        <state>Sao Paulo</state>
        <zip>18031-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>01323-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>04039-004</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>08270-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>01509-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6R 1B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150086</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kladno</city>
        <zip>27259</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <zip>728 80</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague 5</city>
        <zip>150 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 1</city>
        <zip>110 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 2</city>
        <zip>12800</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rakovnik</city>
        <zip>269 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Usti nad Lebem</city>
        <zip>401 13</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Braedstrup</city>
        <zip>8740</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frederiksberg</city>
        <zip>2000F</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Agen Cedex 9</city>
        <zip>47923</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Angers Cedex 01</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arras</city>
        <zip>62000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brest Cedex</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Castelnau Le Lez</city>
        <zip>34170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colombes Cedex</city>
        <zip>92701</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metz-tessy</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier Cedex</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orthez</city>
        <zip>64300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 15</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roanne</city>
        <zip>42328</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen Cedex</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulon</city>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valenciennes Cedex</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vernon</city>
        <zip>27200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruchsal</city>
        <state>Baden-Württemberg</state>
        <zip>76646</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karlsbad</city>
        <state>Baden-Württemberg</state>
        <zip>76307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neckargemünd</city>
        <state>Baden-Württemberg</state>
        <zip>69151</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augsburg</city>
        <state>Bayern</state>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darmstadt</city>
        <state>Hessen</state>
        <zip>64297</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greifswald</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotenburg</city>
        <state>Niedersachsen</state>
        <zip>27342</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paderborn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>33098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Witten</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58455</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nordhausen</city>
        <state>Thüringen</state>
        <zip>99734</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>12099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bottrop</city>
        <zip>46242</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wanchai</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szekszard</city>
        <zip>7100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szentes</city>
        <zip>6600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kochi</city>
        <state>Kerala</state>
        <zip>682026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyderabad</city>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Delhi</city>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pune</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bandung</city>
        <zip>40161</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jakarta</city>
        <zip>10330</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jakarta</city>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medan</city>
        <zip>20152</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Semarang</city>
        <zip>50241</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ballinasloe</city>
        <state>Co. Galway</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chieti</city>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Piacenza</city>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Venezia</city>
        <zip>30122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <zip>705-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liepaja</city>
        <zip>LV 3414</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <zip>LT-50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Selangor</city>
        <zip>68000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arnhem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Enschede</city>
        <zip>7511 JX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoofddorp</city>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zwolle</city>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <zip>0622</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <zip>2024</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palmerston North</city>
        <zip>4414</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wellington South</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fredrikstad</city>
        <zip>1603</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rud</city>
        <zip>1309</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quezon City</city>
        <zip>0850</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quezon City</city>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-066</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>60-631</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>61-848</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>01-138</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <zip>50-326</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2132</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2157</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2191</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0084</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0157</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0181</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roodepoort</city>
        <state>Gauteng</state>
        <zip>1724</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7460</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Somerset West</city>
        <state>Western Cape</state>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Western Cape</state>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valladolid</city>
        <state>Castilla - León</state>
        <zip>47010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palma de Mallorca</city>
        <state>Illes Baleares</state>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Requena</city>
        <state>Valencia</state>
        <zip>46340</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Borås</city>
        <zip>501 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göteborg</city>
        <zip>416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jönköping</city>
        <zip>551 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sundsvall</city>
        <zip>851 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genéve 14</city>
        <state>Genève 14</state>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chur</city>
        <state>Graubünden</state>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lausanne</city>
        <state>Waadt</state>
        <zip>1005</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>10016</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>220</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pathumwan, Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Isleworth</city>
        <state>London</state>
        <zip>TW7 6AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Andorra</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Indonesia</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Peru</country>
    <country>Portugal</country>
    <country>Slovakia</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <results_reference>
    <citation>EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572. Epub 2012 Mar 26.</citation>
    <PMID>22449293</PMID>
  </results_reference>
  <results_reference>
    <citation>Prins MH, Lensing AW. Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism. Thromb J. 2013 Jul 6;11(1):13. doi: 10.1186/1477-9560-11-13.</citation>
    <PMID>23829521</PMID>
  </results_reference>
  <results_reference>
    <citation>Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Raskob GE, Berkowitz SD, Wells PS; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013 Sep 20;11(1):21. doi: 10.1186/1477-9560-11-21.</citation>
    <PMID>24053656</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang Y, Wang C, Chen Z, Zhang J, Liu Z, Jin B, Ying K, Liu C, Shao Y, Jing Z, Meng IL, Prins MH, Pap AF, Müller K, Lensing AW; Chinese EINSTEIN Investigators. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thromb J. 2013 Dec 16;11(1):25. doi: 10.1186/1477-9560-11-25.</citation>
    <PMID>24341332</PMID>
  </results_reference>
  <results_reference>
    <citation>van Bellen B, Bamber L, Correa de Carvalho F, Prins M, Wang M, Lensing AW. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin. 2014 May;30(5):829-37. doi: 10.1185/03007995.2013.879439. Epub 2014 Jan 22.</citation>
    <PMID>24432872</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2007</study_first_submitted>
  <study_first_submitted_qc>February 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2007</study_first_posted>
  <results_first_submitted>November 22, 2012</results_first_submitted>
  <results_first_submitted_qc>January 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 24, 2013</results_first_posted>
  <disposition_first_submitted>December 21, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>December 21, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 22, 2011</disposition_first_posted>
  <last_update_submitted>January 25, 2014</last_update_submitted>
  <last_update_submitted_qc>January 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Factor Xa Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with confirmed acute symptomatic pulmonary embolism (PE) with or without symptomatic deep vein thrombosis (DVT) were recruited at specialized study sites.</recruitment_details>
      <pre_assignment_details>Out of 4843 participants screened, 10 failed screening (6 due to protocol violations, 2 due to investigator decision and another 2 subjects due to technical problems [interactive voice response system did not work properly]). 4833 participants were randomized (2420 to rivaroxaban and 2413 to enoxaparin/VKA).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
          <description>Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)</description>
        </group>
        <group group_id="P2">
          <title>Enoxaparin/VKA</title>
          <description>Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2420"/>
                <participants group_id="P2" count="2413"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="2412"/>
                <participants group_id="P2" count="2405"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2001"/>
                <participants group_id="P2" count="1954"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="419"/>
                <participants group_id="P2" count="459"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="132"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site closed by investigator</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not take study treatment</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="118"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol driven decision point</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical endpoint reached</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical problems</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant convenience</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Observational Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2206">All participants who took any study medication and entered the observational period.</participants>
                <participants group_id="P2" count="2197">All participants who took any study medication and entered the observational period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2165"/>
                <participants group_id="P2" count="2156"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol driven decision point</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
          <description>Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)</description>
        </group>
        <group group_id="B2">
          <title>Enoxaparin/VKA</title>
          <description>Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2419"/>
            <count group_id="B2" value="2413"/>
            <count group_id="B3" value="4832"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Intention-to-treat (ITT) population</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.9" spread="17.3"/>
                    <measurement group_id="B2" value="57.5" spread="17.2"/>
                    <measurement group_id="B3" value="57.7" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>Intention-to-treat (ITT) population</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 - &lt; 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="410"/>
                    <measurement group_id="B2" value="432"/>
                    <measurement group_id="B3" value="842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 - &lt; 60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="794"/>
                    <measurement group_id="B2" value="779"/>
                    <measurement group_id="B3" value="1573"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 - &lt; 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="740"/>
                    <measurement group_id="B2" value="754"/>
                    <measurement group_id="B3" value="1494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="475"/>
                    <measurement group_id="B2" value="448"/>
                    <measurement group_id="B3" value="923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Intention-to-treat (ITT) population</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1309"/>
                    <measurement group_id="B2" value="1247"/>
                    <measurement group_id="B3" value="2556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1110"/>
                    <measurement group_id="B2" value="1166"/>
                    <measurement group_id="B3" value="2276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment</title>
        <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries.</description>
        <time_frame>3-, 6-, or 12-month study treatment period</time_frame>
        <population>The intention-to-treat (ITT) population consisted of all randomized participants with valid informed consent. Participants were analyzed according to the treatment assigned at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin/VKA</title>
            <description>Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment</title>
          <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries.</description>
          <population>The intention-to-treat (ITT) population consisted of all randomized participants with valid informed consent. Participants were analyzed according to the treatment assigned at randomization.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2419"/>
                <count group_id="O2" value="2413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The rivaroxaban to comparator hazard ratio was computed with a 95% CI (confidence interval) (two-sided testing). Based on this model, rivaroxaban would be considered at least as effective as the comparator if the upper limit of the CI was less than 2.0.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Assuming equal efficacy, a total of 88 events will give a power of 90% to demonstrate that rivaroxaban is at least as effective as the comparator, considering a relative non-inferiority upper CI margin for the hazard ratio of 2.0 (two-sided alpha=0.05). The mean overall incidence for the primary efficacy outcome of 3% was expected and therefore 1465 patients per group would be needed. This number was to be adjusted based on the observed overall incidence of symptomatic recurrent VTE.</non_inferiority_desc>
            <p_value>0.0026</p_value>
            <method>Regression, Cox</method>
            <method_desc>Stratified by intend treatment duration, adjusted for presence of active malignancy at baseline</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2067</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
            <estimate_desc>The standard error of the log hazard ratio was estimated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality Until the Intended End of Study Treatment</title>
        <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries.</description>
        <time_frame>3-, 6-, or 12-month study treatment period</time_frame>
        <population>The intention-to-treat (ITT) population consisted of all randomized participants with valid informed consent. Participants were analyzed according to the treatment assigned at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin/VKA</title>
            <description>Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality Until the Intended End of Study Treatment</title>
          <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries.</description>
          <population>The intention-to-treat (ITT) population consisted of all randomized participants with valid informed consent. Participants were analyzed according to the treatment assigned at randomization.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2419"/>
                <count group_id="O2" value="2413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by intend treatment duration, adjusted for presence of active malignancy at baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1500</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
            <estimate_desc>The standard error of the log hazard ratio was estimated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Event for Net Clinical Benefit 1 Until the Intended End of Study Treatment</title>
        <description>Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.</description>
        <time_frame>3-, 6-, or 12-month study treatment period</time_frame>
        <population>The intention-to-treat (ITT) population consisted of all randomized participants with valid informed consent. Participants were analyzed according to the treatment assigned at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin/VKA</title>
            <description>Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Event for Net Clinical Benefit 1 Until the Intended End of Study Treatment</title>
          <description>Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.</description>
          <population>The intention-to-treat (ITT) population consisted of all randomized participants with valid informed consent. Participants were analyzed according to the treatment assigned at randomization.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2419"/>
                <count group_id="O2" value="2413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.275</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Stratified by intend treatment duration, adjusted for presence of active malignancy at baseline</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1499</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>The standard error of the log hazard ratio was estimated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Recurrent PE Until the Intended End of Study Treatment</title>
        <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.</description>
        <time_frame>3-, 6- or 12-month study treatment period</time_frame>
        <population>The intention-to-treat (ITT) population consisted of all randomized participants with valid informed consent. Participants were analyzed according to the treatment assigned at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin/VKA</title>
            <description>Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Recurrent PE Until the Intended End of Study Treatment</title>
          <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.</description>
          <population>The intention-to-treat (ITT) population consisted of all randomized participants with valid informed consent. Participants were analyzed according to the treatment assigned at randomization.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2419"/>
                <count group_id="O2" value="2413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <p_value_desc>nominal p-value</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Stratified by intend treatment duration, adjusted for presence of active malignancy at baseline.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2570</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.93</ci_upper_limit>
            <estimate_desc>The standard error of the log hazard ratio was estimated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Recurrent DVT Until the Intended End of Study Treatment</title>
        <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries.</description>
        <time_frame>3-, 6- or 12-month study treatment period</time_frame>
        <population>The intention-to-treat (ITT) population consisted of all randomized participants with valid informed consent. Participants were analyzed according to the treatment assigned at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin/VKA</title>
            <description>Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Recurrent DVT Until the Intended End of Study Treatment</title>
          <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries.</description>
          <population>The intention-to-treat (ITT) population consisted of all randomized participants with valid informed consent. Participants were analyzed according to the treatment assigned at randomization.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2419"/>
                <count group_id="O2" value="2413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.85</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Stratified by intend treatment duration, adjusted for presence of active malignancy at baseline.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3289</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
            <estimate_desc>The standard error of the log hazard ratio was estimated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinically Relevant Bleeding, Treatment-emergent (Time Window: Until 2 Days After Last Dose)</title>
        <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life.</description>
        <time_frame>3-, 6- or 12-month study treatment period</time_frame>
        <population>The valid-for-safety analysis population consisted of all participants who were randomized with valid informed consent and received at least one dose of anticoagulant study treatment after randomization (i.e. enoxaparin, warfarin, acenocoumarol, rivaroxaban). Participants were analyzed according to the treatment they actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin/VKA</title>
            <description>Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinically Relevant Bleeding, Treatment-emergent (Time Window: Until 2 Days After Last Dose)</title>
          <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life.</description>
          <population>The valid-for-safety analysis population consisted of all participants who were randomized with valid informed consent and received at least one dose of anticoagulant study treatment after randomization (i.e. enoxaparin, warfarin, acenocoumarol, rivaroxaban). Participants were analyzed according to the treatment they actually received.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2412"/>
                <count group_id="O2" value="2405"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3"/>
                    <measurement group_id="O2" value="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <p_value_desc>If the primary efficacy analysis shows that rivaroxaban is non-inferior to the comparator, the principal safety outcome was to be compared between treatment groups to maintain the overall type I error of 0.05 (2-sided) (a closed testing procedure).</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Stratified by intend treatment duration, adjusted for presence of active malignancy at baseline.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08756</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>The standard error of the log hazard ratio was estimated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With All Deaths</title>
        <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries.</description>
        <time_frame>3-, 6- or 12-month study treatment period</time_frame>
        <population>The valid-for-safety analysis population consisted of all participants who were randomized with valid informed consent and received at least one dose of anticoagulant study treatment after randomization (i.e. enoxaparin, warfarin, acenocoumarol, rivaroxaban). Participants were analyzed according to the treatment they actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin/VKA</title>
            <description>Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With All Deaths</title>
          <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries.</description>
          <population>The valid-for-safety analysis population consisted of all participants who were randomized with valid informed consent and received at least one dose of anticoagulant study treatment after randomization (i.e. enoxaparin, warfarin, acenocoumarol, rivaroxaban). Participants were analyzed according to the treatment they actually received.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2412"/>
                <count group_id="O2" value="2405"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All post-randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-emergent (time window: 2 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-emergent (time window: 7 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Other Vascular Events, On-treatment (Time Window: Until 1 Day After Last Dose)</title>
        <description>All pre-defined vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism or vascular death) were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based results/films/images of confirmatory testing, and/or case summaries.</description>
        <time_frame>3-, 6- or 12-month study treatment period</time_frame>
        <population>The valid-for-safety analysis population consisted of all participants who were randomized with valid informed consent and received at least one dose of anticoagulant study treatment after randomization (i.e. enoxaparin, warfarin, acenocoumarol, rivaroxaban). Participants were analyzed according to the treatment they actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin/VKA</title>
            <description>Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Other Vascular Events, On-treatment (Time Window: Until 1 Day After Last Dose)</title>
          <description>All pre-defined vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism or vascular death) were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based results/films/images of confirmatory testing, and/or case summaries.</description>
          <population>The valid-for-safety analysis population consisted of all participants who were randomized with valid informed consent and received at least one dose of anticoagulant study treatment after randomization (i.e. enoxaparin, warfarin, acenocoumarol, rivaroxaban). Participants were analyzed according to the treatment they actually received.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2412"/>
                <count group_id="O2" value="2405"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With the Individual Components of Efficacy Outcomes Until the Intended End of Study Treatment</title>
        <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death.</description>
        <time_frame>3-, 6- or 12-month study treatment period</time_frame>
        <population>The intention-to-treat (ITT) population consisted of all randomized participants with valid informed consent. Participants were analyzed according to the treatment assigned at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin/VKA</title>
            <description>Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With the Individual Components of Efficacy Outcomes Until the Intended End of Study Treatment</title>
          <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death.</description>
          <population>The intention-to-treat (ITT) population consisted of all randomized participants with valid informed consent. Participants were analyzed according to the treatment assigned at randomization.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2419"/>
                <count group_id="O2" value="2413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death (PE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death (PE cannot be excluded)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic PE and DVT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic recurrent PE only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic recurrent DVT only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death (bleeding)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death (cardiovascular)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death (other)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Symptomatic Recurrent VTE (i.e. the Composite of Recurrent DVT or Fatal or Non-fatal PE) During Observational Period</title>
        <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries.</description>
        <time_frame>Up to 30 days after the last intake of study medication</time_frame>
        <population>Participants entering the observational period were participants for whom the investigator indicated on the eCRF (electronic case report form) that the participant entered the observational period or had a confirmed event more than one day and up to 30 days after the last dose as a component of the respective composite outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin/VKA</title>
            <description>Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Symptomatic Recurrent VTE (i.e. the Composite of Recurrent DVT or Fatal or Non-fatal PE) During Observational Period</title>
          <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries.</description>
          <population>Participants entering the observational period were participants for whom the investigator indicated on the eCRF (electronic case report form) that the participant entered the observational period or had a confirmed event more than one day and up to 30 days after the last dose as a component of the respective composite outcome.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2211"/>
                <count group_id="O2" value="2201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality During Observational Period</title>
        <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries.</description>
        <time_frame>Up to 30 days after the last intake of study medication</time_frame>
        <population>Participants entering the observational period were participants for whom the investigator indicated on the eCRF that the participant entered the observational period or had a confirmed event more than one day and up to 30 days after the last dose as a component of the respective composite outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin/VKA</title>
            <description>Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality During Observational Period</title>
          <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries.</description>
          <population>Participants entering the observational period were participants for whom the investigator indicated on the eCRF that the participant entered the observational period or had a confirmed event more than one day and up to 30 days after the last dose as a component of the respective composite outcome.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2213"/>
                <count group_id="O2" value="2203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With an Event for Net Clinical Benefit 1 During Observational Period</title>
        <description>Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.</description>
        <time_frame>Up to 30 days after the last intake of study medication</time_frame>
        <population>Participants entering the observational period were participants for whom the investigator indicated on the eCRF that the participant entered the observational period or had a confirmed event more than one day and up to 30 days after the last dose as a component of the respective composite outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin/VKA</title>
            <description>Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Event for Net Clinical Benefit 1 During Observational Period</title>
          <description>Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.</description>
          <population>Participants entering the observational period were participants for whom the investigator indicated on the eCRF that the participant entered the observational period or had a confirmed event more than one day and up to 30 days after the last dose as a component of the respective composite outcome.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2212"/>
                <count group_id="O2" value="2201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Recurrent DVT During Observational Period</title>
        <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries.</description>
        <time_frame>Up to 30 days after the last intake of study medication</time_frame>
        <population>Participants entering the observational period were participants for whom the investigator indicated on the eCRF that the participant entered the observational period or had a confirmed event more than one day and up to 30 days after the last dose as a component of the respective composite outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin/VKA</title>
            <description>Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Recurrent DVT During Observational Period</title>
          <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries.</description>
          <population>Participants entering the observational period were participants for whom the investigator indicated on the eCRF that the participant entered the observational period or had a confirmed event more than one day and up to 30 days after the last dose as a component of the respective composite outcome.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2210"/>
                <count group_id="O2" value="2201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With the Individual Components of Efficacy Outcomes During Observational Period</title>
        <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death.</description>
        <time_frame>Up to 30 days after the last intake of study medication</time_frame>
        <population>Participants entering the observational period were participants for whom the investigator indicated on the eCRF that the participant entered the observational period or had a confirmed event more than one day and up to 30 days after the last dose as a component of the respective composite outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin/VKA</title>
            <description>Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With the Individual Components of Efficacy Outcomes During Observational Period</title>
          <description>All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death.</description>
          <population>Participants entering the observational period were participants for whom the investigator indicated on the eCRF that the participant entered the observational period or had a confirmed event more than one day and up to 30 days after the last dose as a component of the respective composite outcome.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2213"/>
                <count group_id="O2" value="2203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death (PE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death (PE cannot be excluded)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic PE and DVT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic recurrent PE only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic recurrent DVT only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death (bleeding)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09"/>
                    <measurement group_id="O2" value="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death (cardiovascular)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death (other)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Percentage of Participants With an Event for Net Clinical Benefit 2 Until the Intended End of Study Treatment</title>
        <description>Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding (associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death), cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography (PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.</description>
        <time_frame>3-, 6- or 12-month study treatment period</time_frame>
        <population>The intention-to-treat (ITT) population consisted of all randomized participants with valid informed consent. Participants were analyzed according to the treatment assigned at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin/VKA</title>
            <description>Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Event for Net Clinical Benefit 2 Until the Intended End of Study Treatment</title>
          <description>Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding (associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death), cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography (PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.</description>
          <population>The intention-to-treat (ITT) population consisted of all randomized participants with valid informed consent. Participants were analyzed according to the treatment assigned at randomization.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2419"/>
                <count group_id="O2" value="2413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Percentage of Participants With an Event for Net Clinical Benefit 2 During Observational Period</title>
        <description>Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding (associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death), cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography (PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.</description>
        <time_frame>Up to 30 days after the last intake of study medication</time_frame>
        <population>Participants entering the observational period were participants for whom the investigator indicated on the eCRF that the participant entered the observational period or had a confirmed event more than one day and up to 30 days after the last dose as a component of the respective composite outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin/VKA</title>
            <description>Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Event for Net Clinical Benefit 2 During Observational Period</title>
          <description>Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding (associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death), cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography (PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.</description>
          <population>Participants entering the observational period were participants for whom the investigator indicated on the eCRF that the participant entered the observational period or had a confirmed event more than one day and up to 30 days after the last dose as a component of the respective composite outcome.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2213"/>
                <count group_id="O2" value="2201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
          <description>Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)</description>
        </group>
        <group group_id="E2">
          <title>Enoxaparin/VKA</title>
          <description>Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="504" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="495" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Anaemia folate deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hypercoagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pernicious anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Splenic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cor pulmonale acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cor pulmonale chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Addison's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Adrenal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Diabetes insipidus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Retinal degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Anorectal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Colonic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Diverticulum oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Intestinal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Tooth loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Gastrointestinal dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Implant site thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Device deposit issue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hepatitis chronic active</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Ischaemic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cytolytic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Antiphospholipid syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Abscess soft tissue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Prostate infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Subdiaphragmatic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Joint abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Infectious peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage traumatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Kidney rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Operative haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Splenic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Subcutaneous haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Perirenal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Incision site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cardiac valve replacement complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Blood amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Coagulation time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Coagulation time shortened</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>International normalised ratio abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Ultrasound liver abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Medical observation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Shock hypoglycaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Metabolic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Osteolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Intervertebral disc compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Acute promyelocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Benign oesophageal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Bile duct cancer non-resectable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Glioblastoma multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Mesothelioma malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Metastases to pleura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Myelofibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Neoplasm prostate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Polycythaemia vera</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>T-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Histiocytosis haematophagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Rectal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Ovarian epithelial cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pelvic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Adrenal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Extranodal marginal zone B-cell lymphoma (MALT type)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Gastric neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Rectal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Metastatic gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Inflammatory pseudotumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Clumsiness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Haemorrhagic transformation stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Radicular pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Complex regional pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Post abortion haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Somatoform disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Mental disorder due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Bladder dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis membranous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Urinary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Priapism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Vulval disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Genital haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Prostatic mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pharyngeal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pulmonary venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Mediastinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Dermatomyositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Lichen planus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Rash morbilliform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Miscarriage of partner</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Aortic thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Embolism arterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Iliac artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Varicophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Paradoxical embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Distributive shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1053" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="1065" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="132" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="181" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="188" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="195" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="172" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="162" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="179" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="156" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="147" subjects_at_risk="2405"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="229" subjects_at_risk="2412"/>
                <counts group_id="E2" subjects_affected="205" subjects_at_risk="2405"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

